Chemotherapy use in elderly patients with soft tissue sarcoma: A Population-based study

Cancer Investigation

Volumn 31, Issue 2, 2013, Pages 83-91

  Matushansky, Igor ^a,b   Dela Cruz, Filemon ^a   Insel, Beverly J ^c   Hershman, Dawn L ^a,b,c   Neugut, Alfred I ^a,b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE   (United States)

^c Department of Medicine   (United States)

Author keywords

Chemotherapy; Outcomes Research; Sarcomas of the Soft Tissue

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE;

AGE; AGED; ANGIOSARCOMA; ARTICLE; BIPHASIC SARCOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SIZE; CANCER SURGERY; COMORBIDITY; DERMATOFIBROSARCOMA PROTUBERANS; DRUG USE; EPITHELIOID SARCOMA; FASCIAL SARCOMA; FEMALE; FIBROHISTIOCYTIC SARCOMA; FIBROMYXOSARCOMA; FIBROSARCOMA; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MARRIAGE; MEDICARE; MIXED TYPE SARCOMA; MYXOID SARCOMA; MYXOSARCOMA; POPULATION RESEARCH; PRIORITY JOURNAL; SARCOMA; SOFT TISSUE SARCOMA; SPINDLE CELL SARCOMA; SYNOVIAL SARCOMA; TUMOR VOLUME;

AGE FACTORS; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; FEMALE; HUMANS; MALE; MEDICARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SARCOMA; SEER PROGRAM; SOCIAL CLASS; UNITED STATES;

EID: 84873186139     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.756112     Document Type: Article

References (48)

1. Ferrari A, Sultan I, Huang TT, Rodriguez-Galindo C, Shehadeh A, Meazza C, Ness KK, Casanova M, Spunt SL. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer 2011;57(6):943-949.
2. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee. B Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359(9325): 2235-2241. (Pubitemid 34717977)
3. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol: official journal of the American Society of Clinical Oncology 1998;16(1):197-203. (Pubitemid 28041599)
4. Wilson AN, Davis A, Bell RS, O'Sullivan B, Catton C, Madadi F, Kandel R, Fornasier VL. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 1994;30A(6):746-751. (Pubitemid 24217327)
5. Blay JY, Le Cesne A. Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven.Oncologist 2009;14(10):1013-1020.
6. Bramwell VH. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol: official journal of the American Society of Clinical Oncology 2001: 19(5):1235-1237. (Pubitemid 32202525)
7. Patrikidou A, Domont J, Cioffi A, Le Cesne A. Treating soft tissue sarcomas with adjuvant chemotherapy. Curr Treat Options Oncol 2011;12(1):21-31.
8. Schlieman M, Smith R, Kraybill WG. Adjuvant therapy for extremity sarcomas. Curr Treat Options Oncol 2006;7(6):456-463. (Pubitemid 44697783)
9. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350(9092): 1647-1654.
10. Alvegard TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, Dahl O, Nordentoft AM, Blomqvist C, Rydholm A. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol: official journal of the American Society of Clinical Oncology 1989;7(10):1504-1513. (Pubitemid 19245122)
11. Chang AE, Kinsella T, Glatstein E, Baker AR, SindelarWF, Lotze MT, Danforth DN Jr., Sugarbaker PH, Lack EE, Steinberg SM. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol: official journal of the American Society of Clinical Oncology 1988; 6(9):1491-1500. (Pubitemid 19089039)
12. Gherlinzoni F, Bacci G, Picci P, Capanna R, Calderoni P, Lorenzi EG, Bernini M, Emiliani E, Barbieri E,NormandA.Arandomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations. J Clin Oncol: official journal of the American Society of Clinical Oncology 1986;4(4):552-558. (Pubitemid 16117947)
13. Glenn J, Kinsella T, Glatstein E, Tepper J, Baker A, Sugarbaker P, Sindelar W, Roth J, Brennan M, Costa J, et al. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer 1985;55(6):1206-1214. (Pubitemid 15148960)
14. Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol: official journal of the American Society of Clinical Oncology 1985;3(9):1240-1245. (Pubitemid 15226529)
15. Rosenberg SA, Tepper J, Glatstein E, Costa J, Young R, Baker A, Brennan MF, Semoss EV, Seipp C, Sindelar WF, Sugarbaker P, Wesley R. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 1983;52(3):424-434. (Pubitemid 13073466)
16. Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, Ruka W, Priario J, Wagener T, Burgers M. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcomareduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol: official journal of the American Society of Clinical Oncology 1994;12(6):1137-1149.
17. Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Quali M,Marreaud S, Bramwell VH, Hohenberger P; EORTC Soft Tissue and Bone SarcomaGroup and theNCIC Clinical Trials Group SarcomaDisease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected softtissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012;13(10):1045-1054.
18. Pervaiz N, Colterjohn N, Ferrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008;113(3):573-581.
19. Matushansky I, Taub RN. Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcoma. Nat Rev Clin Oncol 2011;8(7):434-438.
20. Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU 3rd, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM 3rd, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS,Thornton K, vonMehrenM,Wayne J; National Comprehensive Cancer Network Soft Tissue Sarcoma Panel. Soft tissue sarcoma. J Natl Compr Canc Netw 2010;8(6):630-674.
21. Casali PG, Jost L, Steijfer S, Verweij J, Blay JY; ESMO GuidelinesWorking Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):132-136.
22. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol: official journal of the American Society of Clinical Oncology 1999;17(1):150-157. (Pubitemid 29022388)
23. Bramwell VH, Anderson D, Charette ML. Doxorubicinbased chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma 2000;4(3):103-112.
24. Schuetze SM, Patel S. Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? Oncologist 2009;14(10): 1003-1012.
25. Lev D, Pollock RE. Managing elderly soft tissue sarcoma patients-should age drive treatment? Ann Surg Oncol 2010;17(7):1725-1726.
26. O'Connell JB, Maggard MA, Ko CY. Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol 2004;11(11):962-969. (Pubitemid 40486661)
27. Lahat G, Dhuka AR, Lahat S, Lazar AJ, Lewis VO, Lin PP, Feig B, Cormier JN, Hunt KK, Pisters PW, Pollock RE, Lev D. Complete soft tissue sarcoma resection is a viable treatment option for select elderly patients. Ann Surg Oncol 2009;16(9):2579-2586.
28. Al-Refaie WB, Habermann EB, Dudeja V, Vickers SM, Tuttle TM, Jensen EH, Virnig BA. Extremity soft tissue sarcoma care in the elderly: insights into the generalizability of NCI Cancer Trials. Ann Surg Oncol 2010;17(7):1732-1738.
29. Horton JK, Gleason JF Jr., Klepin HD, Isom S, Fried DB, Geiger AM. Age-related disparities in the use of radiotherapy for treatment of localized soft tissue sarcoma. Cancer 2011;117(17):4033-4040.
30. Postosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;32: 732-748.
31. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.Med Care 2002;40(8):IV.
32. Warren JL,Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB. Utility of the SEER-Medicare data to identify chemotherapy use.Med Care 2002;40(8 Suppl):IV-55-61.
33. Du XL, Fang S, Vernon SW, El-Serag H, Shih VT, Davila J, Rasmus ML. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 2007;110(3):660-669. (Pubitemid 47106157)
34. Charlson ME, Pompei P, Ales KL,MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373-383. (Pubitemid 17055592)
35. Klabunde CN, Legler JM,Warren JL, Baldwin LM, Schrag D. A refined comorbiditymeasurement algorithmfor claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17(8):584-590. (Pubitemid 47096709)
36. Klabunde CN, Postosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53(12):1258-1267. (Pubitemid 32007842)
37. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45(6):613-619.
38. Tierney JF,Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and metaanalysis of the published results of randomised clinical trials. Br J Cancer 1995;72(2):469-475.
39. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri G, Apice G, Zmerly H, Serraino D, Picci P. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol: official journal of the American Society of Clinical Oncology 2001;19(5):1238-1247. (Pubitemid 32202526)
40. Petrioli R, Coratti A, Correale P, D'Aniello C, Grimaldi L, Tanzini G, Civitelli S, Marsili S, Messinese S, Marzocca G, Pirtoli L, Francini G. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 2002;25(5):468-473. (Pubitemid 35154951)
41. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol: official journal of the American Society of Clinical Oncology 1993;11(7):1276-1285. (Pubitemid 23199130)
42. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003(3): CD003293.
43. Edmondson JH, Ryan LM, Blum RH, Brooks JS, ShirakiM, Frytak S, Parkinson DR. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol: official journal of the American Society of Clinical Oncology 1993;11(7):1269-1275. (Pubitemid 23199129)
44. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol: official journal of the American Society of Clinical Oncology 1989;7(9):1208-1216. (Pubitemid 19220122)
45. Lorigan P, Verweij J, Papai Z, Rodenhuis S, LeCesne A, Leahy MG, Radford JA, VanGlabbekeMM,Kirkpatrick A, Hogendoorn PC, Blay JY; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol: official journal of the American Society of Clinical Oncology, 2007;25(21):3144-3150. (Pubitemid 47218064)
46. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R,Buesa J, Casali P, SpoonerD,RankinE.DoxorubicinversusCYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol: official journal of theAmerican Society ofClinical Oncology 1995;13(7):1537-1545.
47. Zalupski M,Metch B, Balcerzak S, FletcherWS, Chapman R, Bonnet JD,Weiss GR, Ryan J, Benjamin RS, Baker LH. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991;83(13):926-932.
48. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002;136(5):349-357. (Pubitemid 34183993)